Weekly Analysts’ Ratings Changes for Valeant Pharmaceuticals International (VRX)

A number of firms have modified their ratings and price targets on shares of Valeant Pharmaceuticals International (NYSE: VRX) recently:

• 7/27/2017 - Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $15.00 price target on the stock.
• 7/27/2017 - Valeant Pharmaceuticals International was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The company reduced its debt by $4.3 billion since the first quarter of 2016.The dermatology business saw some positive trends as the average selling price stabilized. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Shares have underperformed the broader industry.”
• 7/17/2017 - Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $35.00 price target on the stock.
• 7/17/2017 - Valeant Pharmaceuticals International was given a new $19.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
• 7/17/2017 - Valeant Pharmaceuticals International was given a new $10.00 price target on by analysts at J P Morgan Chase & Co. They now have a “hold” rating on the stock.
• 7/14/2017 - Valeant Pharmaceuticals International had its “underweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $10.00 price target on the stock.
• 7/14/2017 - Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Wells Fargo & Company.
• 7/14/2017 - Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $18.00 price target on the stock.
• 7/13/2017 - Valeant Pharmaceuticals International was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The company reduced its debt by $4.3 billion since the first quarter of 2016.The dermatology business saw some positive trends as the average selling price stabilized. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Shares have underperformed the broader industry.”
• 7/12/2017 - Valeant Pharmaceuticals International had its price target raised by analysts at TD Securities from $15.00 to $20.00. They now have a “hold” rating on the stock.
• 7/6/2017 - Valeant Pharmaceuticals International had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $10.00 price target on the stock.
• 7/3/2017 - Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Wells Fargo & Company.
• 6/30/2017 - Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $35.00 price target on the stock.
• 6/29/2017 - Valeant Pharmaceuticals International was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
• 6/28/2017 - Valeant Pharmaceuticals International had its price target raised by analysts at Cantor Fitzgerald from $18.00 to $23.00. They now have a “positive” rating on the stock. They wrote, “On 5/2/17 Valeant held its annual shareholder meeting. Interestingly, the company’s Say on Pay” vote on executive compensation passed with a ~65% majority, despite both ISS and Glass Lewis voting against the plan. We think this reflects the fact that Valeant’s shareholders support the new CEO and CFO. We also believe that the Board has been re-invigorated with the addition of John Paulson. This was announced 6/19/17.””
• 6/27/2017 - Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Wells Fargo & Company.
• 6/23/2017 - Valeant Pharmaceuticals International was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
• 6/20/2017 - Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Mizuho. They now have a $8.00 price target on the stock.
• 6/19/2017 - Valeant Pharmaceuticals International was given a new $19.00 price target on by analysts at Royal Bank Of Canada. They now have a “sector perform” rating on the stock.
• 6/17/2017 - Valeant Pharmaceuticals International is now covered by analysts at Guggenheim. They set a “buy” rating and a $18.00 price target on the stock.
• 6/16/2017 - Valeant Pharmaceuticals International is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $18.00 price target on the stock.
• 6/16/2017 - Valeant Pharmaceuticals International was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
• 6/13/2017 - Valeant Pharmaceuticals International had its “market perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $19.00 price target on the stock.
• 6/12/2017 - Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Wells Fargo & Company.
• 6/9/2017 - Valeant Pharmaceuticals International had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $15.00 price target on the stock.
• 6/8/2017 - Valeant Pharmaceuticals International was given a new $14.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
• 6/2/2017 - Valeant Pharmaceuticals International was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

Valeant Pharmaceuticals International, Inc. (VRX) opened at 17.13 on Friday. The company has a 50 day moving average of $15.83 and a 200-day moving average of $13.35. The company’s market cap is $5.96 billion. Valeant Pharmaceuticals International, Inc. has a one year low of $8.31 and a one year high of $32.74.

Get Valeant Pharmaceuticals International Inc alerts:

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $1.93. The firm had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. Valeant Pharmaceuticals International’s quarterly revenue was down 11.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.08) earnings per share. On average, equities analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 20,000 shares of the stock in a transaction that occurred on Thursday, May 11th. The shares were purchased at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the transaction, the director now owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc and related companies with MarketBeat.com's FREE daily email newsletter.